Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Directorate Change

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/19/2019 | 02:01am EDT

19 August 201907:00 BST

AstraZeneca appoints Michel Demaré to its Board of Directors

AstraZeneca today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee.

Leif Johansson, Chairman of AstraZeneca, said: "We are delighted to appoint Michel Demaré as a Director. He has a great deal of industrial, financial and board-level experience across a range of sectors including science and technology, that will enable him to contribute well to the work of our Board and Audit Committee."

Michel Demaré is a Non-Executive Director of Vodafone Group Plc and a member of the Supervisory Board of Louis Dreyfus Company Holdings BV. He is Vice-Chairman and Chairman-designate of the IMD executive business school in Lausanne, and a member of the Advisory Board of the Department of Banking and Finance at the University of Zurich.

Mr Demaré was Vice-Chairman of UBS Group AG from 2010 to 2019, Chairman of Syngenta and the Syngenta Foundation for Sustainable Agriculture from 2013 to 2017 and Chairman of SwissHoldings from 2013 to 2015.

Mr Demaré joined ABB Ltd in 2005 as Chief Financial Officer (CFO) and member of the Group Executive Committee.  For most of 2008, he acted as the interim Chief Executive Officer of ABB.  From late 2008 to 2011, he combined his role as CFO with that of President of Global Markets.

He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005.  Prior to that, he spent 18 years at the Dow Chemical Company, holding various treasury and risk management positions in Belgium, France, the US and Switzerland.  Between 1997 and 2002, Mr Demaré was CFO of the Global Polyolefins and Elastomers division.  He began his career as a banking officer in the multinational banking division of Continental Illinois' Belgian subsidiary.

Mr Demaré graduated with an MBA from the Katholieke Universiteit Leuven, Belgium, and holds a degree in applied economics from the Université Catholique de Louvain, Belgium.

Except as set out above, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com (http://www.astrazeneca.com/) and follow us on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Malmberg
Hägerstrand
Michele Meixell US +1 302 885 2677

Investor
Relations
Thomas Kudsk +44 203 749 5712
Larsen
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharmaceuticals +44 203 749 5711
Gruvris (cardiovascular,
metabolism)
Nick Stone BioPharmaceuticals +44 203 749 5716
(respiratory, renal)
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Corporate access, +44 203 749 5824
Kretzmann retail investors
US toll-free +1 866 381 72 77

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

https://news.cision.com/astrazeneca/r/directorate-change,c2883535

https://mb.cision.com/Main/309/2883535/1091767.pdf

(c) 2019 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
ABB LTD -0.78% 18.365 Delayed Quote.-3.05%
ASTRAZENECA 0.68% 6965 Delayed Quote.17.76%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
10/12LONDON MARKETS: Brexit Hopes Sends British Pound To Highest Level Of Johnson ..
DJ
10/10Recharged hopes of Brexit deal, trade truce power UK shares
RE
10/07ASTRAZENECA : Launches Signature STEM Program to Empower Students to Live Health..
BU
10/04ASTRAZENECA : Gets FDA Approval for Fasenra Auto-Injector Pen
DJ
10/04ASTRAZENECA : FASENRA® (benralizumab) Approved in the US for Self-administration..
BU
10/04ASTRAZENECA : Fasenra approved in the US for self-administration in a new pre-fi..
PU
10/04ASTRAZENECA : FDA Approves Self-Administered Fasenra Pen
DJ
10/04ASTRAZENECA : Fasenra approved in the US for self-administration
PU
10/04ASTRAZENECA : Fasenra approved in the US for self-administrationin a new pre-fil..
AQ
10/01UK stocks retreat as weak U.S. data adds to global growth fears
RE
More news
Financials (USD)
Sales 2019 23 943 M
EBIT 2019 6 402 M
Net income 2019 2 218 M
Debt 2019 11 423 M
Yield 2019 3,20%
P/E ratio 2019 50,9x
P/E ratio 2020 34,8x
EV / Sales2019 5,27x
EV / Sales2020 4,79x
Capitalization 115 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,04  $
Last Close Price 87,43  $
Spread / Highest target 48,3%
Spread / Average Target 7,55%
Spread / Lowest Target -27,6%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA17.76%115 078
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287